INTRODUCTION {#s1}
============

Viral genomic mutations may contribute to HCC development. HBV nonstructural X protein (HBx) is a key regulatory protein of the virus and is at the intersection of HBV infection, replication, pathogenesis, and possibly carcinogenesis. HBx has different consequences for hepatocyte physiology because HBV-infected cells are targeted by the immune system or as hepatocytes, in which HBx is expressed, and undergo transformation and progression to HCC. In addition, HBx can influence apoptotic and cell cycle regulatory pathways \[[@R1]\].

However, the roles that HBx mutations play in hepatocarcinogenesis remain controversial, particularly for the basal core promoter (BCP) A1762T/G1764A dual mutation. Several prospective studies have demonstrated that patients with an A1762T/G1764A dual mutation were more predisposed to HCC than those with the wild type and that HBV mutations, including A1762T/G1764A, are associated with an increased risk of HCC \[[@R2]\]. However, a recent study using global data found no significant difference in BCP mutations between HCC and non-HCC patients with HBV genotype C, and the differences between chronic hepatitis B (CHB) and liver cirrhosis (LC) and between LC and HCC were not significant, although the mutant ratio increased with disease progression. \[[@R3]\].

In this meta-analysis, we summarized the prevalence of A1762T/G1764A mutations from ASC, CHB, LC and HCC patients. We also analyzed the BCP mutation rates in chronic HBV infection, including HCC patients grouped by HBV genotype and HBeAg status, hoping that the results might provide useful insights into the risk of HCC occurrence.

RESULTS {#s2}
=======

Study and patient characteristics {#s2_1}
---------------------------------

A total of 1883 abstracts were reviewed. From these articles, 163 that were closely related to the current subject were retrieved. The study selection process is summarized in Figure [1](#F1){ref-type="fig"}. Finally, 52 case-control or cohort studies \[[@R4]-[@R55]\] were included in the meta-analysis. A total of 10,240 individuals with chronic HBV infection were included, 3729 of whom had HCC. The baseline characteristics and quality scores of the studies examined in this meta-analysis are listed in Table [2](#T2){ref-type="table"}.

![Flow program of study selection](oncotarget-07-12525-g001){#F1}

###### Quality criteria for the included studies[\*](#tfn_001){ref-type="table-fn"}

  Quality parameter                       Score                                                                                                         
  --------------------------------------- ----------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------
  Study design                            Cohort study or nested case-control study       Incidence case-control study. Prevalence case-control study   \-
  No. of case subjects                    \>100                                           50-100                                                        \<50
  Source of population                    Community-based or from two or more countries   ≥2 hospitals                                                  1 hospitals
  Mutation detection method               DNA direct sequencing                           Innogenetics line-probe assay                                 Single-strand conformation polymorphism; Mass spectrometer
  Matching of case and control subjects                                                                                                                 
  Confounder group 1                      Age and sex                                     Age or sex                                                    None
  Confounder group 2                      HBeAg status and HBV genotype                   HBeAg status or HBV genotype                                  None

-, designs other than cohort or nested, incidence, or prevalence case-control not included in meta-analysis; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

###### Baseline characteristics of studies included in the meta-analysis

  Study                 Design   Country or area                   No. of cases   No. of controls   Detection method    HBV genotype       Matching factors   Quality score             
  --------------------- -------- --------------------------------- -------------- ----------------- ------------------- ------------------ ------------------ --------------- ---- ---- -----
  Asim 2010             PCC      India                             150            136               SSCP                A, D               \-                 \-              \-   \-   ≤4
  Bahramali 2008        Cohort   Iran                              7              55                Sequencing          D                  \-                 \-              \-   \-   ≤4
  Bai 2011              Cohort   China                             152            136               Sequencing          B, C, others       \-                 \-              \-   \-   7
  Baptista 1999         PCC      South Africa                      59             52                Sequencing          NA                 \+                 \-              \-   \-   5-7
  Blackberg 2003        PCC      Sweden, others                    16             19                Sequencing          A, B, C, D         \-                 \+              \+   \+   ≥8
  Chen 2006             PCC      Taiwan                            50             102               INNO-LiPA           B, C               \+                 \-              \-   \-   5-7
  Chen 2008             PCC      Taiwan                            80             160               Sequencing          B, C, D            \+                 \+              \+   \-   5-7
  Chen 2009             PCC      Taiwan                            222            300               Sequencing          B, C               \+                 \+              \-   \-   5-7
  Chen 2012             PCC      China                             156            310               Sequencing          B, C               \+                 \+              \-   \-   5-7
  Cho 2011              PCC      Korea                             69             125               Sequencing          C                  \-                 \-              \-   \-   ≤4
  Choi 2009             PCC      Korea                             42             46                Sequencing          C                  \-                 \-              \-   \-   ≤4
  Chou 2008             NCC      Taiwan                            154            316               Sequencing          A,B,C              \+                 \-              \-   \-   ≥8
  Chu 2012              PCC      Taiwan                            80             120               Sequencing          B, C               \+                 \+              \+   \-   4-6
  Constantinescu 2014   Cohort   Romania                           94             390               Sequencing          A, D               \-                 \-              \-   \-   5
  Datta 2014            PCC      India                             22             46                Sequencing          A, C, D            \-                 \-              \-   \-   ≤4
  Elkady 2008           PCC      Mongolia                          23             25                Sequencing          A, D               \-                 \-              \-   \-   ≤4
  Fan 2011              PCC      China                             34             38                Sequencing          B, C               \+                 \+              \+   \-   5-7
  Guo 2008              NCC      China                             58             71                Sequencing          B, C               \+                 \+              \-   \-   ≥8
  Ito 2006              ICC      Japan, United States, Hong Kong   40             80                Sequencing          C                  \+                 \+              \+   \+   ≥8
  Jang 2007             Cohort   Korea                             6              23                Sequencing          C                  \-                 \-              \+   \+   ≥8
  Kao 2012              PCC      Taiwan                            56             112               Sequencing          B, C               \+                 \-              \-   \-   4-5
  Kim 2008              PCC      Korea                             60             124               Sequencing          C                  \-                 \-              \-   \+   5-7
  Kim 2009              PCC      Korea                             135            135               Sequencing          C                  \+                 \+              \+   \-   5-7
  Kuang 2005            PCC      Thailand                          34             68                Mass spectrometer   NA                 \+                 \+              \-   \-   ≤4
  Lee 2011              PCC      Korea                             31             65                Sequencing          C                  \-                 \-              \-   \-   ≤4
  Li 2013               Cohort   China                             102            105               Sequencing          C                  \-                 \-              \-   \-   6
  Lin 2005              PCC      Taiwan                            32             142               Sequencing          B, C, Others       \-                 \-              \+   \-   ≤4
  Liu 2006              PCC      Taiwan                            200            160               INNO-LiPA           B, C               \-                 \-              \-   \-   ≤4
  Livingston 2007       ICC      United States                     47             1129              INNO-LiPA           A, C, D, F         \+                 \+              \-   \-   ≤4
  Lyu 2013              ICC      Korea                             318            234               Sequencing          C                  \-                 \-              \-   \-   5
  Malik 2012            PCC      India                             118            294               Sequencing          A, D               \-                 \-              \-   \-   5
  Muroyama 2006         PCC      Japan                             39             36                Sequencing          C                  \+                 \+              \-   \+   5-7
  Panigrahi 2012        PCC      India                             20             132               Sequencing          A, C, D            \-                 \-              \-   \-   ≤4
  Park 2014             PCC      Korea                             132            310               Sequencing          C                  \-                 \-              \-   \-   5
  Qu 2014               ICC      China                             152            131               Sequencing          B, C               \+                 \-              \-   \-   5-7
  Sakamoto 2006         PCC      Japan, Philippines                31             69                Sequencing          A, B, C            \-                 \+              \-   \-   5-7
  Shinkai 2007          PCC      Japan                             80             80                Sequencing          C                  \+                 \+              \+   \+   ≥8
  Song 2005             PCC      Vietnam                           48             74                Sequencing          NA                 \-                 \-              \-   \-   ≤4
  Tanaka 2006           PCC      Japan, Hong Kong                  148            180               Sequencing          C                  \+                 \+              \+   \-   ≥8
  Tangkijvanich 2010    ICC      Thailand                          60             60                Sequencing          B, C               \+                 \+              \+   \+   6
  Tong 2007             ICC      United States                     101            67                Sequencing          A, B, C, D         \-                 \-              \-   \-   5-7
  Tong 2013             ICC      United States                     173            240               Sequencing          A, B, C, D, E, F   \+                 \-              \-   \-   5-7
  Truong 2007           PCC      Japan, Vietnam                    32             88                Sequencing          C                  \-                 \-              \+   \+   5-7
  Utama 2009            PCC      Indonesia                         48             123               Sequencing          B, C               \-                 \-              \-   \-   5
  Wang 2007             PCC      China                             47             164               Sequencing          B, C               \-                 \+              \-   \-   5-7
  Xu 2010               PCC      China                             60             120               Sequencing          A, B, C            \+                 \+              \-   \-   4-6
  Yin 2011              PCC      China                             190            1269              Sequencing          B, C               \+                 \+              \-   \-   ≥8
  Yuan 2007             PCC      China                             34             207               Sequencing          B, C               \-                 \+              \-   \+   5-7
  Yuan 2009             ICC      China                             49             97                Sequencing          NA                 \+                 \-              \-   \-   5-7
  Zhang 2007            Cohort   China                             32             32                Sequencing          NA                 \+                 \+              \-   \-   6-8
  Zheng 2011            PCC      China                             156            185               Sequencing          B, C, E            \-                 \-              \-   \-   7
  Zhu 2008              NCC      China                             20             83                Sequencing          C                  \+                 \+              \+   \+   ≥8

Abbreviations: NA, not available; PCC, prevalence case-control; NCC, nested case-control; ICC, incidence case-control; SSCP, Single-strand conformation polymorphism; INNO-LiPA, Innogenetics line-probe assay.

Prevalence of A1762T/G1764A mutations from ASC, CHB, LC and HCC {#s2_2}
---------------------------------------------------------------

Heterogeneity was significant among the included studies \[[@R4]-[@R38], [@R40]-[@R55]\] when comparing the prevalence of A1762T/G1764A dual mutations between HCC and non-HCC patients (*P* \< 0.00001, I^2^ = 82%). Thus, a random-effects model was used. Our data revealed that more HCC patients had A1762T/G1764A dual mutations compared with non-HCC patients (66.5% vs. 39.8%, OR = 3.05, 95% CI = 2.35-3.95, *P* \< 0.00001, Table [3](#T3){ref-type="table"} and [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}).

###### Frequency of BCP A1762T/G1764A dual mutations from chronic HBV-infected patients, including HCC

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Comparisons   Studies                                                                    A1762T/G1764A dual mutation, n (%)   Heterogeneity   OR   95% CI       *P* value                      
  ------------- -------------------------------------------------------------------------- ------------------------------------ --------------- ---- ------------ ----------- ------ ----------- ------------
  HCC           \[[@R4]-[@R38], [@R40]-[@R55]\]                                            2480/3729 (66.5)                     270.4           50   \< 0.00001   82          3.05   2.35-3.95   \< 0.00001

  Non-HCC       2594/6511 (39.8)                                                                                                                                                                 

  HCC           \[[@R5], [@R9], [@R12]-[@R14], [@R16], [@R18], [@R23], [@R25], [@R28],\    544/808 (67.3)                       33.38           18   0.02         46          1.55   1.06-2.26   0.02
                [@R30], [@R34], [@R36], [@R41], [@R46]-[@R48], [@R51], [@R55]\]                                                                                                                  

  LC            441/708 (62.3)                                                                                                                                                                   

  HCC           \[[@R5], [@R9], [@R12], [@R13], [@R20]-[@R23], [@R25], [@R28]-[@R30],\     927/1300 (71.3)                      72.49           20   \< 0.00001   72          2.87   1.96-4.20   \< 0.00001
                [@R33], [@R34], [@R36], [@R41], [@R47], [@R48], [@R51], [@R53], [@R55]\]                                                                                                         

  CHB           796/1566 (50.8)                                                                                                                                                                  

  HCC           \[[@R5], [@R7]-[@R9], [@R16], [@R17], [@R22]-[@R25], [@R30], [@R31],\      591/924 (64.0)                       70.33           15   \< 0.00001   79          5.59   3.17-9.83   \< 0.00001
                [@R36], [@R41], [@R44], [@R51]\]                                                                                                                                                 

  ASC           246/1068 (23.0)                                                                                                                                                                  

  LC-HCC        \[[@R12], [@R16], [@R47], [@R54]\]                                         327/476 (68.7)                       6.57            3    0.09         54          2.06   0.99-4.28   0.05

  Non-LC-HCC    93/165 (56.4)                                                                                                                                                                    

  Non-LC-HCC    \[[@R12], [@R16], [@R47], [@R54]\]                                         93/165 (56.4)                        7.60            3    0.05         61          2.16   1.08-4.32   0.03

  CHB/ASC       225/466 (48.3)                                                                                                                                                                   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: HCC, hepatocellular carcinoma; LC, liver cirrhosis; CHB, chronic hepatitis B; ASC, asymptomatic HBsAg carriers; LC-HCC, cirrhotic hepatocellular carcinoma; Non-LC-HCC, non-cirrhotic hepatocellular carcinoma.

In addition, we performed a subgroup analysis to compare A1762T/G1764A dual mutations between ASC, CHB, LC and HCC patients. Compared to LC patients, HCC patients had a higher risk of A1762T/G1764A dual mutations (OR = 1.55, 95% CI = 1.06-2.26, *P* = 0.02, Table [3](#T3){ref-type="table"} and [Supplementary Figure S2](#SD1){ref-type="supplementary-material"}). Moreover, a subgroup analysis of four studies \[[@R12], [@R16], [@R47], [@R54]\] with a random-effects model revealed no statistically significant difference between cirrhotic HCC (LC-HCC) and non-cirrhotic HCC (non-LC-HCC) patients in terms of the frequency of A1762T/G1764A dual mutations (OR = 2.06, 95% CI = 0.99-4.28, *P* = 0.05, Table [3](#T3){ref-type="table"} and [Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). This result should be reevaluated in studies with larger samples sizes. We performed another comparison of BCP dual mutations between non-LC-HCC and non-LC patients, including CHB and ASC patients. Using a random-effects model, a meta-analysis of four studies \[[@R12], [@R16], [@R47], [@R54]\] showed that the non-LC-HCC patients had a significantly higher frequency of A1762T/G1764A dual mutations compared with the CHB and ASC patients (OR = 2.16, 95% CI = 1.08-4.32, *P* = 0.03, Table [3](#T3){ref-type="table"} and [Supplementary Figure S4](#SD1){ref-type="supplementary-material"}). Given the above results, we assumed that BCP A1762T/G1764A dual mutations might promote hepatocarcinogenesis even without progression to cirrhosis.

Additionally, A1762T/G1764A dual mutations contributed to a higher risk of HCC occurrence compared with CHB patients (OR = 2.87, 95% CI = 1.96-4.20, *P* \< 0.00001, Table [3](#T3){ref-type="table"} and [Supplementary Figure S5](#SD1){ref-type="supplementary-material"}). A similar trend in A1762T/G1764A dual mutations was found in HCC and ASC patients. HCC patients had a significantly higher frequency of A1762T/G1764A dual mutations than the ASC patients (OR = 5.59, 95% CI = 3.17-9.83, *P* \< 0.00001, Table [3](#T3){ref-type="table"} and [Supplementary Figure S6](#SD1){ref-type="supplementary-material"}). In summary, the frequency of A1762T/G1764A dual mutations increased in this manner: from ASC to chronic disease, and then to HCC ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}).

A1762T/G1764A mutations in different HBV genotypes {#s2_3}
--------------------------------------------------

Heterogeneity was significant among the included studies \[[@R12], [@R20], [@R30], [@R31], [@R39], [@R47]\], which described A1762T/G1764A dual mutations from chronic HBV infection in HBV genotypes B and C. Chronic HBV-infected patients with genotype B had a significant lower incidence of A1762T/G1764A dual mutations compared with those with genotype C (OR = 0.30, 95% CI = 0.18-0.52, *P* \< 0.0001, Figure [2.1](#F2){ref-type="fig"}); no heterogeneity was found when we compared BCP dual mutations between HBV genotypes B and C in HCC patients (*P* = 0.27, I^2^ = 24%). Similarly, HCC patients with HBV genotype B had lower levels of A1762T/G1764A dual mutations compared with those with genotype C (OR = 0.34, 95% CI = 0.13-0.94, *P* = 0.04, Figure [2.2](#F2){ref-type="fig"}). In HBV genotype C subjects, BCP A1762T/G1764A dual mutations contributed to significantly higher risk for HCC developing compared with non-mutation ones (OR = 3.47, 95% CI = 2.28-5.27, *P* \< 0.00001, Figure [3.1](#F3){ref-type="fig"}). Heterogeneity was significant between studies comparing HCC occurrence in HBV genotype B (*P* \< 0.00001, I^2^ = 93%), no difference was found (*P* = 0.34, Figure [3.2](#F3){ref-type="fig"}).

![BCP A1762T/G1764A dual mutations in HBV genotype B and C from chronic HBV infection patients, including HCC](oncotarget-07-12525-g002){#F2}

![HCC occurrence between BCP A1762T/G1764A dual mutation and non-BCP dual mutation patients with HBV genotype C and genotype B](oncotarget-07-12525-g003){#F3}

A1762T/G1764A mutations from HBeAg-positive and HBeAg-negative patients {#s2_4}
-----------------------------------------------------------------------

Nine studies \[[@R7], [@R12]-[@R14], [@R29], [@R37], [@R40], [@R42], [@R54]\] reported A1762T/G1764A dual mutations based on HBeAg status in chronic HBV infection. Heterogeneity was significant among these studies (P \< 0.00001, I^2^ = 81%), and no significance in BCP A1762T/G1764A mutations was observed in either HBeAg-positive or HBeAg-negative chronic HBV-infected patients (OR = 1.06, 95% CI = 0.63-1.78, *P* = 0.83, Figure [4.1](#F4){ref-type="fig"}). In HCC, there was no difference of A1762T/G1764A mutations between HBeAg-positive and HBeAg-negative patients (OR = 1.38, 95% CI = 0.84-2.27, *P* = 0.20, Figure [4.2](#F4){ref-type="fig"}).

![Comparison of BCP A1762T/G1764A dual mutations grouped by HBeAg status from chronic HBV infection patients, including HCC](oncotarget-07-12525-g004){#F4}

DISCUSSION {#s3}
==========

HCC is one of the most lethal cancers \[[@R56], [@R57]\]. The most common naturally occurring mutations in the BCP A1762T/G1764A dual mutation has been associated with hepatocarcinogenesis, but conflicts still exist \[[@R1],[@R3]\]. Our meta-analysis showed that the A1762T/G1764A dual mutation was present at statistically significantly higher frequencies in HCC patients than in non-HCC controls, including LC, CHB and ASC patients. As the disease progressed, the risk of the A1762T/G1764A dual mutation in ASC, CHB, LC and HCC patients increased. Therefore, we hypothesized that A1762T/G1764A dual mutation might play a vital role in promoting disease progression in chronic HBV infection. Several previous case series have also shown a higher frequency of BCP T1762/A1764 mutation in patients with cirrhosis than in inactive carriers or patients with chronic hepatitis \[[@R16], [@R30], [@R58]\]. Our results confirmed this observation. However, the BCP A1762T/G1764A dual mutation is increasingly more prevalent as chronic HBV infection progresses from the asymptomatic HBsAg carrier state to liver cirrhosis or HCC, indicating that these mutations accumulate before the diagnosis of HCC. This finding suggests that BCP dual mutation may be a promising biomarker for predicting the clinical outcomes of patients with chronic HBV infection, particularly in terms of predicting whether they will develop HCC. Additionally, we performed a subgroup analysis that revealed no statistically significant difference in terms of the frequency of A1762T/G1764A dual mutations in liver cirrhotic HCC and non-cirrhotic HCC patients. Thus, we assumed that BCP A1762T/G1764A dual mutations might promote hepatocarcinogenesis even without progression to cirrhosis. Because the samples of non-cirrhotic patients with HCC in this investigation were relatively small, this hypothesis must be proven based on future studies with larger patient cohorts.

HBV genotype is associated with the risk of HCC. One possible reason for this association is that HBV mutations may be more common in some HBV genotypes than in others \[[@R2]\]. In this research, we found that chronic HBV-infected patients with genotype B had a significantly lower risk of A1762T/G1764A dual mutations compared with those with genotype C. In HCC, patients with HBV genotype C suffered higher A1762T/G1764A dual mutations compared with those with genotype B. Previous reports have shown that patients with genotype C infection have a higher positive rate of HBeAg, more severe liver disease and higher risk of developing HCC \[[@R30], [@R59]-[@R61]\]. On the basis of previous research and our results, we suggested that HBV genotype C patients tend to have a higher proportion of BCP T1762/A1764 mutations in conjunction with chronic HBV infection, including HCC \[[@R31], [@R58]\].

It has been suggested that the A1762T/G1764A double mutation in the BCP region can reduce the synthesis of HBeAg and enhance viral replication. However, this analysis found no significance of BCP A1762T/G1764A mutations from HBeAg-positive and HBeAg-negative chronic HBV-infected patients. The same finding was true for HCC patients. When introduced into wild-type HBV genomes, the BCP dual mutation indeed decreased HBeAg expression and enhanced viral genome replication of about twofold \[[@R60],[@R62]\]. Transfection studies have shown that the T1762A/G1764A dual mutations decrease the level of pre-C mRNA by 50% to 70%, thereby inhibiting HBeAg production. A previous report showed that HBeAg titers are closely correlated with BCP mutation, and HBeAg-positive patients of genotype C infection had a higher prevalence of the A1762T/G1764A mutations \[[@R63]\]. Although no difference of BCP dual mutations was found in our meta-analysis, further research focusing on the mechanisms and the relationship between BCP mutation and HBeAg status is needed.

This meta-analysis had the following limitations. First, patients in the included studies had different HBV genotypes, different ethnicities, leading to significant heterogeneity; second, most of the included studies had small samples, with mid- to low-quality designs. In the future, high-quality, well-designed research focused on the mechanisms of BCP dual mutation in the progression of chronic HBV infection and HCC must be performed.

Based on our results, we could conclude that BCP A1762T/G1764A dual mutations are associated with disease progression and HCC occurrence in chronic HBV-infected patients. Additionally, this mutation might promote hepatocarcinogenesis even without progression to cirrhosis. Considered the frequency ratio of A1762T/G1764A dual mutation from ASC, CHB, LC and HCC, we suggested that BCP dual mutation should be screened in the CHB and LC patients.

MATERIALS AND METHODS {#s4}
=====================

Search strategy and study selection {#s4_1}
-----------------------------------

We searched PubMed, Ovid, Web of Science, and Cochrane Library databases for studies published to June 1, 2015. The following medical subject headings were used: "hepatocellular carcinoma;" "hepatitis B virus X protein;" "mutation;" "basal core promoter;" "A1762T;" "G1764A;" and "variation." Electronic searches were supplemented with manual searches of reference lists used in all retrieved review articles, primary studies, and abstracts from meetings to identify other studies not found in the electronic searches. The literature was searched by two authors (Z Yang and L Zhuang) independently.

Two authors independently selected studies and discussed them with each other when inconsistencies were found. Articles that satisfied the following criteria were included: (1) case-control or cohort studies, (2) HCC and control subjects, including ASC, CHB or LC patients, (3) BCP A1762T/G1764A dual mutations (for HBV mutation), (4) HCC outcomes, and (5) available full texts. If the duration and sources of the study population recruitment overlapped by more than 30% in two or more papers by the same authors, we only included the most recent study or the study with the larger number of HCC patients. The following exclusion criteria were applied: (1) studies that included patients who were coinfected with hepatitis A, C, D, E virus or human immunodeficiency virus, had alcohol-related liver diseases, or had previously received antiviral treatments, (2) studies without control subjects, and (3) studies that only investigated A1762T or G1764A single mutations.

Data extraction and methodological quality assessment {#s4_2}
-----------------------------------------------------

In our evaluation of the BCP A1762T/G1764A dual mutant, subjects with either a single mutation or a deletion at either site were not included in the analysis. Two researchers independently read the full texts and extracted the following information: publication data; study design; sample size; HBV genotypes; country or area; and study matching factors. The methodological qualities of the included studies were assessed according to the report by Liu et al. \[[@R64]\]. A 12-point scoring system was used that was based on factors that indicated good-quality observational studies, as shown in Table [1](#T1){ref-type="table"}. Two authors (ZG Yang and LP Zhuang) independently assessed the study quality, and inconsistency was discussed with another reviewer-author (X Chen), who acted as an arbiter.

Definitions {#s4_3}
-----------

All diagnoses should be made according to the guidelines. ASC were defined as being seropositive for HBsAg for at least 6 months, having no evidence of LC or HCC based on the clinical criteria and undergoing ultrasound examination, with normal alanine aminotransferase (ALT). CHB was defined as being seropositive for HBsAg for at least 6 months, having persistent or intermittently elevated ALT levels or a liver biopsy showing chronic hepatitis with moderate or severe necroinflammation, with no clinical evidence of LC. The patients with LC were diagnosed by histologic analysis of liver biopsy specimens or by findings of repeated ultrasonography that were suggestive of cirrhosis and supplemented with clinical criteria indicating portal hypertension (i.e., the presence of ascites, thrombocytopenia, and esophageal varices). HCC was defined by at least one of the following criteria: (1) liver biopsy or (2) elevated alpha-fetoprotein levels and sonography, computed tomography or magnetic resonance imaging evidence.

Statistical methods {#s4_4}
-------------------

The effect measures of interest were odds ratios (ORs) and the corresponding 95% confidence intervals (CIs). Heterogeneity across studies was informally assessed by visually inspecting forest plots and then formally estimated by Cochran\'s Q test in which chi-squared distribution was used to make inferences regarding the null hypothesis of homogeneity (considered significant at P \< 0.10). A rough guide to our interpretation of I^2^ follows: 0% to 40% shows that heterogeneity may not be important30% to 60% corresponds to moderate heterogeneity50% to 90% indicates substantial heterogeneity75% to 100% indicates considerable heterogeneity \[[@R65], [@R66]\]

If the eligibility of some studies in the meta-analysis was uncertain because of missing information, a sensitivity analysis was performed by conducting the meta-analysis twice: in the first meta-analysis, all studies were included; in the second meta-analysis, only studies that were definitely eligible were included. A fixed-effects model was initially used for our meta-analyses; a random-effects model was then used in the presence of heterogeneity. Description analysis was performed when the quantitative data could not be pooled. Review Manager software, version 5.1, was used for data analysis. All statistical tests were two-tailed, and differences with *P* \< 0.05 were considered statistically significant.

SUPPLEMENTARY MATERIAL FIGURES AND TABLE {#s5}
========================================
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